Streetbeat News

Analyst Ratings

TTWO

Oppenheimer analyst Andrew Uerkwitz has reiterated an Outperform rating on Take-Two Interactive (NASDAQ:TTWO) and maintained a price target of $157.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 2:02 pm

QSR

Oppenheimer analyst Brian Bittner has reiterated an Outperform rating on Restaurant Brands Intl (NYSE:QSR) and maintained a price target of $83.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 2:01 pm

FLYW

Flywire (NASDAQ:FLYW) has received 9 analyst ratings in the last quarter, with 8 being bullish or somewhat bullish and 1 being indifferent. The average price target is $37.78, which is higher than the current price of $35.08, implying an upside. The average price target has increased by 9.51% over the past month.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 2:01 pm

ALDX

Aldeyra Therapeutics (NASDAQ:ALDX) has received 5 analyst ratings in the last quarter, with 4 being bullish and 1 somewhat bullish. The average price target is $16.8, indicating an upside from the current price of $7.4899. However, this average has decreased by 40.0% from the previous average price target of $28.00.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 2:00 pm

RLAY

Oppenheimer analyst Matthew Biegler has reiterated his 'Outperform' rating on Relay Therapeutics (NASDAQ:RLAY), maintaining a price target of $33.

Portfolio Pulse from richadhand@benzinga.com

August 09, 2023 | 2:00 pm

ADTN

Over the past 3 months, 6 analysts have published their opinion on Adtran (NASDAQ:ADTN) stock, all of them being bullish. The average price target is $13.5, implying an upside from the current price of $7.35. This average represents a 28.95% decrease from the previous average price target of $19.00.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 2:00 pm

UBX

Over the past 3 months, 4 analysts have published their opinion on Unity Biotechnology (NASDAQ:UBX) stock. The average price target is $7.0, implying an upside from the current price of $2.41. The average price target has increased by 75.0% over the past month.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 2:00 pm

RAPT

In the last quarter, RAPT Therapeutics (NASDAQ:RAPT) received 3 bullish and 1 somewhat bullish ratings from analysts. The average 12-month price target for the company is $39.25, representing an 8.72% decrease from the previous average price target of $43.00.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 2:00 pm

DOCS

Truist Securities analyst Jailendra Singh has maintained a 'Hold' rating on Doximity (NYSE:DOCS) and lowered the price target from $33 to $28.

Portfolio Pulse from jenniferd'souza@benzinga.com

August 09, 2023 | 2:00 pm

DUOL

Analysts have provided bullish ratings for Duolingo (NASDAQ:DUOL) in the last quarter, with 2 bullish and 1 somewhat bullish ratings. The company has an average 12-month price target of $163.33, a 2.2% decrease from the previous average price target of $167.00.

Portfolio Pulse from Benzinga Insights

August 09, 2023 | 2:00 pm